Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples